Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Novartis

Status and phase: Completed; Phase 4

Conditions: Prevention of Meningococcal Infection

Treatments: Biological: Meningococcal C conjugate vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00310713

Impact N° 1637

M14P5E1

Details and patient eligibility

About

Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine

Enrollment: 33 patients

Sex: All

Ages: 12 to 13 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy children

Exclusion criteria

• Known hypersensitivity to any vaccine products
• Any immunodeficiency, genetic anomaly or severe acute or chronic illness

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

33 participants in 5 patient groups

Group 1

Experimental group

Treatment:

Biological: Meningococcal C conjugate vaccine

Group 2

Experimental group

Treatment:

Biological: Meningococcal C conjugate vaccine

Group 3

Experimental group

Treatment:

Biological: Meningococcal C conjugate vaccine

Group 4

Experimental group

Treatment:

Biological: Meningococcal C conjugate vaccine

Group 5

Experimental group

Treatment:

Biological: Meningococcal C conjugate vaccine